ArticleCancer research communications2022

Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma.

Robert H I Andtbacka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.